Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:HRMY NASDAQ:VCEL NASDAQ:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$11.92+3.1%$11.29$0.88▼$17.25$476.80M1.23320,879 shs24,219 shsHRMYHarmony Biosciences$30.15-1.1%$29.43$25.52▼$40.87$1.75B0.97750,644 shs431,487 shsVCELVericel$34.73-1.2%$33.72$28.95▼$45.97$1.77B1.15710,587 shs383,195 shsZYMEZymeworks$25.61+2.0%$25.63$11.02▼$29.75$1.87B1.2662,803 shs477,950 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+3.11%-11.77%-26.10%+20.16%+540.86%HRMYHarmony Biosciences-1.12%+0.20%-5.69%+3.40%-12.61%VCELVericel-1.19%+5.15%+1.05%-8.82%-15.44%ZYMEZymeworks+1.99%+7.02%-10.23%+12.72%+2,560,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$11.92+3.1%$11.29$0.88▼$17.25$476.80M1.23320,879 shs24,219 shsHRMYHarmony Biosciences$30.15-1.1%$29.43$25.52▼$40.87$1.75B0.97750,644 shs431,487 shsVCELVericel$34.73-1.2%$33.72$28.95▼$45.97$1.77B1.15710,587 shs383,195 shsZYMEZymeworks$25.61+2.0%$25.63$11.02▼$29.75$1.87B1.2662,803 shs477,950 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+3.11%-11.77%-26.10%+20.16%+540.86%HRMYHarmony Biosciences-1.12%+0.20%-5.69%+3.40%-12.61%VCELVericel-1.19%+5.15%+1.05%-8.82%-15.44%ZYMEZymeworks+1.99%+7.02%-10.23%+12.72%+2,560,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.50Moderate Buy$21.6781.77% UpsideHRMYHarmony Biosciences 2.27Hold$40.8935.62% UpsideVCELVericel 2.50Moderate Buy$55.4059.52% UpsideZYMEZymeworks 2.91Moderate Buy$38.0048.38% UpsideCurrent Analyst Ratings BreakdownLatest ANL, HRMY, ZYME, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026ANLAdlai Nortye JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.005/11/2026VCELVericel Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/8/2026VCELVericel HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$64.005/8/2026HRMYHarmony Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$25.00 ➝ $29.005/8/2026ZYMEZymeworks Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$33.00 ➝ $34.005/1/2026HRMYHarmony Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/29/2026HRMYHarmony Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/27/2026ZYMEZymeworks Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/20/2026ZYMEZymeworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ANLAdlai Nortye HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$16.00 ➝ $20.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M95.36N/AN/A($0.21) per share-56.76HRMYHarmony Biosciences$868.45M2.01$3.14 per share9.59$15.73 per share1.92VCELVericel$276.26M6.42$0.55 per share63.28$6.98 per share4.98ZYMEZymeworks$81.26M23.01N/AN/A$2.24 per share11.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$35.53MN/AN/AN/AN/AN/AN/AN/A8/6/2026 (Estimated)HRMYHarmony Biosciences$158.69M$2.4812.167.850.2016.20%17.19%11.99%8/4/2026 (Estimated)VCELVericel$16.52M$0.4282.6941.84N/A7.35%6.41%4.61%7/30/2026 (Estimated)ZYMEZymeworks-$81.13M-$1.37N/A80.03N/A-126.92%-37.97%-25.31%8/6/2026 (Estimated)Latest ANL, HRMY, ZYME, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026HRMYHarmony Biosciences$0.76$0.55-$0.21$0.55$220.84 million$215.39 million5/7/2026Q1 2026VCELVericel-$0.15-$0.12+$0.03-$0.12$63.68 million$68.43 million5/7/2026Q1 2026ZYMEZymeworks-$0.10-$0.59-$0.49-$0.59$24.38 million$2.41 million3/31/2026Q4 2025ZYMEZymeworksN/A-$0.59N/A-$0.59N/A$2.41 million3/2/2026Q4 2025ZYMEZymeworks-$0.35-$0.55-$0.20-$0.55$21.78 million$2.52 million2/26/2026Q4 2025VCELVericel$0.45$0.45N/A$0.45$92.66 million$92.92 million2/24/2026Q4 2025HRMYHarmony Biosciences$0.84$0.38-$0.46$0.38$240.04 million$243.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai NortyeN/A0.650.65HRMYHarmony Biosciences0.153.583.56VCELVericelN/A5.184.79ZYMEZymeworksN/A10.8210.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%HRMYHarmony Biosciences86.23%VCELVericelN/AZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/AHRMYHarmony Biosciences11.00%VCELVericel7.60%ZYMEZymeworks33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12740.00 millionN/ANot OptionableHRMYHarmony Biosciences20057.89 million51.53 millionOptionableVCELVericel30051.07 million47.19 millionOptionableZYMEZymeworks46073.02 million48.55 millionN/AANL, HRMY, ZYME, and VCEL HeadlinesRecent News About These CompaniesZymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC OptionalityMay 22 at 8:03 AM | seekingalpha.comZymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from BrokeragesMay 18, 2026 | americanbankingnews.comVanguard Group Inc. Increases Position in Zymeworks Inc. $ZYMEMay 15, 2026 | marketbeat.comZymeworks Authorizes 2026 Share Repurchase Program, Affirms LiquidityMay 14, 2026 | tipranks.comZymeworks’ Earnings Call Balances Progress And PressureMay 14, 2026 | theglobeandmail.comZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockMay 14, 2026 | financialpost.comFZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockMay 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Insmed (INSM)May 14, 2026 | theglobeandmail.comZymeworks Announces Participation in Upcoming Investor ConferencesMay 13, 2026 | financialpost.comFZymeworks Announces Participation in Upcoming Investor ConferencesMay 13, 2026 | globenewswire.comZymeworks Inc. 2026 Q1 - Results - Earnings Call PresentationMay 12, 2026 | seekingalpha.comHere's What Analysts Are Forecasting For Zymeworks Inc. (NASDAQ:ZYME) After Its First-Quarter ResultsMay 11, 2026 | finance.yahoo.comA Look At Zymeworks (ZYME) Valuation After Earnings Miss And Key FDA And Capital Return UpdatesMay 9, 2026 | finance.yahoo.comZymeworks Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comZymeworks Inc. (ZYME) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comZymeworks (NASDAQ:ZYME) Trading Down 8.9% After Earnings MissMay 8, 2026 | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) StockMay 8, 2026 | marketbeat.comZymeworks (ZYME) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comZymeworks (NASDAQ:ZYME) Posts Quarterly Earnings Results, Misses Estimates By $0.49 EPSMay 7, 2026 | marketbeat.comZymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comZymeworks Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANL, HRMY, ZYME, and VCEL Company DescriptionsAdlai Nortye NASDAQ:ANL$11.92 +0.36 (+3.11%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$11.87 -0.05 (-0.42%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Harmony Biosciences NASDAQ:HRMY$30.15 -0.34 (-1.12%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$30.16 +0.01 (+0.03%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Vericel NASDAQ:VCEL$34.73 -0.42 (-1.19%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$34.74 +0.01 (+0.01%) As of 05/22/2026 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Zymeworks NASDAQ:ZYME$25.61 +0.50 (+1.99%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$24.58 -1.03 (-4.02%) As of 05/22/2026 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
